Activation of Innate and not Adaptive Immune system in Gluten Sensitivity

Similar documents
Baboons Affected by Hereditary Chronic Diarrhea as a Possible Non-Human Primate Model of Celiac Disease

Gluten Sensitivity Fact from Myth. Disclosures OBJECTIVES 18/09/2013. Justine Turner MD PhD University of Alberta. None Relevant

Is It Celiac Disease or Gluten Sensitivity?

Primary Care Update January 26 & 27, 2017 Celiac Disease: Concepts & Conundrums

Diseases of the gastrointestinal system Dr H Awad Lecture 5: diseases of the small intestine

Diagnostic Testing Algorithms for Celiac Disease

Challenges in Celiac Disease. Adam Stein, MD Director of Nutrition Support Northwestern University Feinberg School of Medicine

Celiac Disease and Non Celiac Gluten Sensitivity. John R Cangemi, MD Mayo Clinic Florida

New Insights on Gluten Sensitivity

Celiac Disease: The Future. Alessio Fasano, M.D. Mucosal Biology Research Center University of Maryland School of Medicine

Disclosures GLUTEN RELATED DISORDERS CELIAC DISEASE UPDATE OR GLUTEN RELATED DISORDERS 6/9/2015

November Laboratory Testing for Celiac Disease. Inflammation in Celiac Disease

Celiac Disease Ce. Celiac Disease. Barry Z. Hirsch, M.D. Baystate Pediatric Gastroenterology and Nutrition. baystatehealth.org/bch

Larazotide Acetate. Alessio Fasano, M.D. Mucosal Biology Research Center and Center for Celiac Research University of Maryland School of Medicine

BIOPSY AVOIDANCE IN CHILDREN: THE EVIDENCE

See Policy CPT CODE section below for any prior authorization requirements

Functional Medicine Is the application of alternative holistic measures to show people how to reverse thyroid conditions, endocrine issues, hormone

Gluten-Free China Gastro Q&A

CELIAC SPRUE. What Happens With Celiac Disease

Celiac Disease: The Quintessential Autoimmune Disease Ivor D. Hill, MB, ChB, MD.

Diagnosis Diagnostic principles Confirm diagnosis before treating

EAT ACCORDING TO YOUR GENES. NGx-Gluten TM. Personalized Nutrition Report

DDW WRAP-UP 2012 CELIAC DISEASE. Anju Sidhu MD University of Louisville Gastroenterology, Hepatology and Nutrition June 21, 2012

Presentation and Evaluation of Celiac Disease

DEAMIDATED GLIADIN PEPTIDES IN COELIAC DISEASE DIAGNOSTICS

Celiac disease Crohn s disease Ulcerative colitis Pseudomembranous colitis

Epidemiology. The old Celiac Disease Epidemiology:

CELIAC DISEASE - GENERAL AND LABORATORY ASPECTS Prof. Xavier Bossuyt, Ph.D. Laboratory Medicine, Immunology, University Hospital Leuven, Belgium

Celiac & Gluten Sensitivity; serum

2013 NASPGHAN FOUNDATION

The Gluten Free Diet and Potential Alternative Therapies: The Road Ahead

Meredythe A. McNally, M.D. Gastroenterology Associates of Cleveland Beachwood, OH

Peter HR Green MD. Columbia University New York, NY

Immune mediated enteropathies. Aurora Tatu Bern 26/07/2017

Spectrum of Gluten Disorders

Coeliac disease: pathogenesis. Riccardo Troncone

OHTAC Recommendation

FOXP3 EXPRESSION IN HUMAN CANCER CELLS

Celiac Disease 1/13/2016. Objectives. Question 1. Understand the plethora of conditions or symptoms that require testing for Celiac Disease (CD)

Celiac Disease. Sheryl Pfeil, MD The Ohio State University Division of Gastroenterology, Hepatology, and Nutrition. January 2015

No relevant financial relationships to disclose

Celiac disease is a unique disorder that is both a food

Therapeutical implication of regulatory cells and cytokines in celiac disease

Celiac Disease. Definition & Facts. What is celiac disease? How common is celiac disease? Who is more likely to develop celiac disease?

Our simple 3 step process to help you discover if gluten could be a problem for you!

Diet Isn t Working, We Need to Do Something Else

Celiac Disease and Gluten Sensitivity: New Tests and Approaches

Celiac Disease: The Past and The Present

Evidence Based Guideline

Name of Policy: Human Leukocyte Antigen (HLA) Testing for Celiac Disease

Saeeda Almarzooqi, 1 Ronald H. Houston, 2 and Vinay Prasad Introduction

L y mp h o c y t i c D i s o r d e r s of t h e. What does too many mean? Unifying theory 2/24/2011

Follow-up Management of Patients with Celiac Disease: Resource for Health Professionals

5/27/2014 WEBINAR. Suggested CDR Learning Codes: 3000, 5000, 5110, 5220; Level 2

What do Clinical Scientists Knead to Know About Gluten? A Gluten-Free World. Much More Than the 6/2/15

Gluten sensitivity in Multiple Sclerosis Experimental myth or clinical truth?

Coeliac disease. Do I have coeliac. disease? Diagnosis, monitoring & susceptibilty. Laboratory flowsheet included

Celiac Disease. Samuel Gee (1888) first described Celiac disease in On the Coeliac Affection Gluten sensitive entropathy Non-tropical sprue

Gluten and the skin: Celiac disease and gluten sensitivity for the dermatologist

Current Management of Celiac Disease and Identifying an Appropriate Patient Population(s) for Pharmacologic Therapies in Adult Patients

Am I a Silly Yak? Laura Zakowski, MD. No financial disclosures

The Gluten Syndrome. Why? Gluten Syndrome vs. Celiac Symptoms Testing Implementing Social Issues Caveats

Sheila E. Crowe, MD, FACG

Nicole Cerillo, RD Kogan Celiac Center

NICHOL'S FIVE CENTS. Why is Gluten so bad? A monthly e-newsletter dedicated to helping you Go Further, Move Faster & Be Stronger!

Alliance for Best Practice in Health Education

Should you be Gluten Free? Gluten Sensitivity: Today s Most Under Recognized Medical Condition. Disclosures. Gluten Confusion 2/10/2014

Celiac Disease. Detlef Schuppan HARVARD MEDICAL SCHOOL

Celiac Disease. Etiology. Food Intolerance:Celiac Disease and Gluten Sensitivity-A Guide for Healthy Lifestyles

Esperanza Garcia-Alvarez MD Medical Director Pediatric Celiac Center at Advocate Children s Hospital

What is celiac disease?

Organic - functional. Opposing views. Simple investigation of GI disorders. The dollar questions. Immune homeostasis of mucosa

Kamran Rostami, MD, PhD Gastroenterology Unit, Milton Keynes, University Hospital UK

Living with Coeliac Disease Information & Support is key

FPIES ANOTHER DISEASE ABOUT WHICH YOU SHOULD KNOW OBJECTIVES FPIES FPIES 11/10/2016. What is that? Robert P. Dillard, M.D.

Slides and Resources.

4/6/18. A clinical and practical presentation of Celiac Disease. Objectives. History of Celiac disease. Lacey Yzeik, MS, RDN, LDN Clinical Dietitian

Use of ancient wheat crops for the diet of non-celiac gluten sensitive patients

The first and only fully-automated, random access, multiplex solution for Celiac IgA and Celiac IgG autoantibody testing.

prevalence 181 Atopy patch test, see Patch test

DR.RAJIV SHARMA BOOK SERIES 2

What is celiac disease? How common is celiac disease? Who gets celiac disease?

Understanding CELIAC DISEASE

The first and only fully-automated, random access, multiplex solution for Celiac IgA and Celiac IgG autoantibody testing.

The lab is open, the tests are available. Read on for much more information.

588-Complete Dietary Antigen Testing

Genetics and Epidemiology of Celiac Disease

Celiac disease: Beyond Glutenfree. AmerEl Sayed, MD LSGE- Annual Meeting 2014

Non-celiac gluten sensitivity: questions still to be answered despite increasing awareness

Celiac Disease For Dummies By Sheila Crowe, Ian Blumer READ ONLINE

Understanding Celiac Disease

Celiac Disease. Gluten-Sensitive Enteropathy Celiac Sprue Non-tropical Sprue

All about Gluten? Celiac disease, gluten sensitivity, wheat sensitivity, and other considerations

Sequoia Education Systems, Inc. 1

Understanding Celiac Disease

A young woman with fatigue

CELIAC DISEASE. Molly Jennings Deb McCafferty MS, RD

Celiac Disease: You ve Come A Long Way Baby!

Gluten enteropathy: current views on diagnosis and treatment

Coeliac disease catering gluten-free

Transcription:

Activation of Innate and not Adaptive Immune system in Gluten Sensitivity Update: Differential mucosal IL-17 expression in gluten sensitivity and the autoimmune enteropathy celiac disease A. Sapone, L. de Magistris, M. Cammarota, M.T. Giuliano, M. De Rosa, M. Carteni, C. Tolone, A. Papparella, R. Stefanile, G.Mazzarella, M.I. Russo, P. Esposito, A. Frattino, A. Fasano, G. Riegler 1

ABSTRACT There are cases of gluten reaction defined as gluten sensitivity (GS) in which neither an allergic (wheat allergy) nor an autoimmune [celiac disease (CD)] mechanism can be advocated. Recent evidences suggest that early changes in intestinal permeability (IP) and activation of both innate and adaptive immune responses are involved in CD pathogenesis. Conversely, no data are currently available on the mechanisms leading to GS. Aim was to investigate the changes in IP, TJ protein genes expression, and innate and adaptive immune responses in GS. Biopsy samples were obtained from 28 GS patients, 53 pts with active CD, 16 patients with CD in remission, and 37 healthy controls (age range: 5 years -5 years). Claudin (CL) 1, CL2, CL3, CL4, ZO-1, and TLR1, TLR2 and TLR4, FOXP3, and TGF-ß gene expression were performed by Real-time PCR. IP was evaluated by means of the lactulose/mannitol test (LA/MA). The number of intraepithelial lymphocytes (IELs) was detected with CD3 and TCR-?d immunostaining and examined by counting the peroxidase stained cells. ELISA analysis of IL6, IL8, TNFa, was conducted on PBMC of all patients. CL3 and CL4 expressions were significantly increased in GS subjects compared to CD patients (p<.1). In GS patients, these changes were associated to a lower IP (.1±.8) that inversely correlated to CL4 gene expression (r= -.6318; p<.5) compared to healthy controls (.18±.9). Conversely, in CD patients an overexpression of CL2 was observed that was associated to increased IP (.53±.48) and that returned to baseline following implementation of a gluten free diet. Interestingly, immunohistochemical examination of biopsy specimen showed a lower number of CD3+IELs in GS pts compared to active CD pts (27.25/1 and 36.3/1 enterocytes respectively) that correlated with MARSH -1 lesions, with no changes in TCR γδ IELs. In a subgroup of GS pts, intestinal TLR1 and TLR2 expression was increased and these changes were associated to an increased production of cytokines related to the innate but not adaptive immune responses. Compared to CD patients, GS subjects showed normal IP and activation of the innate but not adaptive immune responses. These changes cause only minimal gut inflammation, suggesting that in GS lack of adaptive immune response involvement prevent the autoimmune gut insult typical of CD. 2

Background The evolution of human race did not plan for the advent and exposure to wheat gluten. The engineering of gluten-containing grains 1, years ago represented a mistake of evolution that created the conditions for human diseases related to gluten exposure. 3

Background: Reaction to gluten can involve an allergic (wheat allergy) or an autoimmune [celiac disease (CD)] mechanism. However, there are cases of gluten reaction in which neither mechanism is involved. These cases are defined as gluten sensitivity (GS). Recent evidences suggest that early changes in intestinal permeability (IP) and activation of the innate immune system through Toll Like Receptor (TLR) signaling pathway may both be involved in the early steps of CD pathogenesis. Conversely, no data are currently available on the role of intestinal barrier dysfunction in the pathogenesis of GS. 4

Aims:. To investigate the changes in IP and TJ protein genes expression in GS patients;. To establish whether these changes are related to activation of the innate and/or adaptive immune response. 5

Materials and Methods: Biopsy samples were obtained from 26 GS patients, 3 patients with active CD, 6 patients with CD in remission, and 14 healthy controls. Quantitative gene expression of tight junctions proteins Claudin (CL) 1, CL2, CL3, CL4, ZO-1, Occludin and of TLR1, TLR2 and TLR4 was performed by Real-time PCR. IP was evaluated by means of the lactulose/mannitol test (LA/MA). The degree of intestinal mucosal damage was evaluated according to the Marsh classification. The numbers of IELs were examined using CD3 and TCR-γδ immunostaining. 6

Materials and Methods: GS inclusions criteria: Gastrointestinal or extra-intestinal symptoms mimicking CD; Negative CD serology; Negative response for atopy patch test (APT) to wheat and prick test. 7

Results: Clinical and laboratory characteristics of the study subjects Healthy CD GS Age of diagnosis (mean ± SE) 29.1 ± 5.1 35.2 ± 3.3 28.9 ± 4.4 Sex (F/M) 2/16 15/36 18/1 Intestinal Symptoms Extra-intestinalSymptoms Dyspepsia None -Chronic diarrhea -Abdominal pain -Weight fluctuation - Weakness - Smelling, fatty stool -Bone or joint pain - Osteoporosis - Behavioral changes - Tingling leg numbness - Muscle cramps - Missed menstrual periods - Infertility - Recurrent miscarriage - Delayed growth - Tooth discoloration -Unexplained anemia -Diarrhea - Abdominal pain -Weight fluctuation -Gas -Bone or joint pain -Osteoporosis - Leg numbness -Muscle cramps -Unexplained anemia - Glossitis -Thyroiditis EMA % Positive (92.3%) Negative A % Positive (53.8%) Positive (45.5%) ttg % Positive (84.6%) Negative HLA DQ2/DQ8 28.6% 92.3%) 36.4%) PRICK/ RAST/ PRIST test Not tested Negative Negative LA/MA test Normal (<.3) Altered (>.3) Normal (<.3) 8

Nr CD3+IELs/1 enterocytes Nr TCR-γδ IEL/1 enterocytes A B Results :Duodenal I CD3+ IELs C C 4 X CD3+IELs TCR-γδ IELs 1 9 8 7 6 5 4 3 2 1 Healthy CD active GS CD treated 5 45 4 35 3 25 2 15 1 5 Healthy CD active GS CD treated A= Gluten Sensitive B= Controls C= CD Active 9

Results: Change in Intestinal Permeability in GS and CD patients In GS patients IP (.14±.15) was similar to that detected in healthy controls (,19±,18). Conversely, in CD the increased expression of CL2 was associated to an increase in IP (.52±.48). In CD patients in remission, IP (.14±.4) returned to normal levels. 1

Results: Intercellular TJ expression CD.1.8.6 CLDN1 1.5 1. CLDN2 5 4 3 CLDN3 **.4.5 2.2 1.. 2. 1.5 1..5 CLDN4 * 2.5 2. 1.5 1..5 ZO1 15 1 5 OCLN.. CL3 and CL4 expressions were significantly increased in GS subjects compared to CD patients (p<.1), while no changes in other TJ protein genes expression were detected. Conversely, in CD patients an over-expression of CL2 was observed that was associated to increased IP and that returned to baseline following a gluten free diet. *,** P <.1 GS vs Celiac active pts * r (IP vs CL4)=,6318; p=,5 11

Results: TLR signaling pathway involvement.25.2.15.1.5 * TLR1 TLR2.4 * **.3.2.1.25.2.15.1.5 TLR4... TLR1 and TLR2, but not TLR4 resulted significantly increased in GS *, **(p<,5) respect to normal controls, while CD showed only a not significant increase of TLR1 12

Results: Cytokines expression in cultured PBMC 8 7 7 6 5 4 3 2 1 Healthy CD active GS CD gfd 6 5 4 3 2 1 Healthy CD active GS CD gfd medium PT BSA medium PT BSA IL6 TNFa 35 3 25 2 15 1 5 Healthy CD active GS CD gfd PBMC released IL6, IL8 and TNFa in all groups after stimulation with pt-gliadin. medium PT BSA IL8 13

Results: regulatory molecules gene expression TGFB1 FOXP3 6.1.8 4.6 2.4.2..25.2.15.1.5 IL17A * 2. 1.5 1..5 HMGB1 ** ***.. CD pts showed a decreased expression of FOXP3 that was associated to a significantly increased of IL 17 compared to normal control and GS pts, while HMGB1 was significantly decreased in both GS and CD pts. * P=,4 CD vs C **,*** P<,5 CD and Gs vs C 14

Conclusions: Compared to CD patients, GS subjects showed normal IP. Up-regulation of CL4 in GS patients is statistically significant and inversely correlated to IP. GS patients showed an increase in CD3+ IEL but no tissue damage. The significant over expression of TLR 1 and TLR2 in GS but not in CD may reflect the activation of the innate immune system in this condition. PBMC derived cytokines expression is similarly elicitated by gliadin in both CD and GS. IL 17 activation pathway only in CD may suggest that in GS the response to gluten exposure is limited to activation of the innate immune system without involvement of the adaptive immune response. Gluten Sensitivity showing a peculiar TJ proteins pattern, confirms to be different from celiac disease. 15